Breaking News

Tweet TWEET

Amsterdam Molecular Therapeutics(in Liquidation) Announces Delisting and Expected

Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in liquidatie)
(Euronext: AMT) announces that NYSE Euronext has determined and announced that as of 19
November 2012, AMT's shares will be delisted from NYSE Euronext in Amsterdam, the
Netherlands with 16 November 2012 being the last trading date. 
On 12 September 2012, the account and justification (rekening en verantwoording) as
prepared by AMT's liquidators was made available for inspection at the Chamber of Commerce
of Amsterdam (De Ruyterkade 5, Amsterdam) and at AMT's offices (Meibergdreef 61, Amsterdam
Zuidoost), and on 14 September 2012 notice of the same was given in a national newspaper.
Absent any surplus following the final settlement of the remaining assets and liabilities,
no plan of distribution (plan van verdeling) was prepared. 
Assuming that no action (verzet) will be instituted against the account and
justification, AMT's liquidators expect to finalise the liquidation on or shortly
following 19 November 2012. There will not be any (final) distributions to AMT
shareholders in the context of the finalisation of the liquidation or otherwise. When the
liquidation ends, AMT and its shares shall cease to exist. 
Certain statements in this press release are "forward-looking statements" including
those that refer to management's plans and expectations for future operations, prospects
and financial condition. Words such as "strategy," "expects," "plans," "anticipates,"
"believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets"
and other words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on current expectations only. Undue reliance should
not be placed on these statements because, by their nature, they are subject to known and
unknown risks and can be affected by factors that are beyond the control of AMT (in
liquidation). Actual results could differ materially from current expectations due to a
number of factors and uncertainties. AMT (in liquidation) expressly disclaims any intent
or obligation to update any forward-looking statements herein except as required by law. 
Further information on AMT (in liquidation), can be found on AMT (in liquidation)'s
website http://www.amtbiopharma.com. 
PRN NLD 
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Nov/06/2012 13:29 GMT